| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | William I Bensinger | |
| P2860 | cites work | Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma | Q33348936 |
| Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect | Q34487436 | ||
| A comparison of allografting with autografting for newly diagnosed myeloma | Q34577703 | ||
| Drug insight: thalidomide as a treatment for multiple myeloma | Q36304004 | ||
| Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Wo | Q36424524 | ||
| Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects | Q40706569 | ||
| Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. | Q43488186 | ||
| Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma | Q43632773 | ||
| Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma | Q44071975 | ||
| Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome | Q44083618 | ||
| Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma | Q44139126 | ||
| Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality | Q44189564 | ||
| 153Sm EDTMP for bone marrow ablation prior to stem cell transplantation for haematological malignancies | Q44201995 | ||
| Follow‐up of patients with progressive multiple myeloma undergoing allografts after reduced‐intensity conditioning | Q44418467 | ||
| 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials | Q44429171 | ||
| Non-myeloablative allogeneic peripheral stem cell transplantation for multiple myeloma. | Q44838370 | ||
| Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation | Q44888557 | ||
| Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. | Q45076113 | ||
| A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma | Q45138883 | ||
| Outcome of myeloablative allogeneic stem cell transplantation in multiple myeloma with a 153Sm-EDTMP-based preparative regimen | Q46368527 | ||
| Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma | Q46509828 | ||
| Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma | Q46720756 | ||
| Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. | Q46907944 | ||
| Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. | Q54267460 | ||
| Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. | Q54657115 | ||
| Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: Limited efficacy of graft-versus-tumor activity | Q61651657 | ||
| Graft-versus-myeloma effect: proof of principle | Q70903400 | ||
| Graft-versus-myeloma effect in two cases | Q71060552 | ||
| Graft-versus-myeloma effect | Q71264400 | ||
| Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect | Q73014175 | ||
| Graft-versus-myeloma after withdrawal of immunosuppression following allogeneic peripheral stem cell transplantation | Q73072066 | ||
| Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation | Q73117300 | ||
| Donor leukocyte infusions for multiple myeloma | Q73375198 | ||
| Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers | Q73427004 | ||
| Mixed hematopoietic chimerism after hematopoietic stem cell allografts | Q74616585 | ||
| Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation | Q74823803 | ||
| Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation | Q76381510 | ||
| Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma | Q77227215 | ||
| Graft-versus-myeloma | Q77597294 | ||
| Multiple myeloma | Q78556841 | ||
| Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning | Q78834266 | ||
| Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning | Q79421927 | ||
| Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma | Q82192536 | ||
| Prolonged overall survival with second on-demand autologous transplant in multiple myeloma | Q83300465 | ||
| P433 | issue | 4 | |
| P921 | main subject | stem cell transplantation | Q65592366 |
| P304 | page(s) | 783-795 | |
| P577 | publication date | 2007-12-01 | |
| P1433 | published in | Best Practice and Research: Clinical Haematology | Q15755888 |
| P1476 | title | Is there still a role for allogeneic stem-cell transplantation in multiple myeloma? | |
| P478 | volume | 20 |
| Q33412636 | A prospective study of lenalidomide monotherapy for relapse after Allo-SCT for multiple myeloma |
| Q34149903 | A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma |
| Q41031177 | Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation |
| Q64890377 | Multiple Myeloma: What Do We Do About Immunodeficiency? |
| Q36148528 | Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma |
| Q84946022 | Sudden significant total protein concentration change: not an analytical problem |
| Q37596718 | Symptoms after hospital discharge following hematopoietic stem cell transplantation |
Search more.